Synnocare focuses on the development of drug-resistant targets, independently builds a series of research platforms based on the combination of artificial intelligence (AI) and multi-omics technology (Omics), and can accurately target cancer cells based on synthetic lethal tumor treatment, and accurately screen patients according to the genetic mutations of cancer cells. In the future, synthetic lethal will play a huge role in the precision treatment of tumors.
1、SLKG——Knowledge graph and target prediction platform of Synthetic lethality 2、SLMiner——Identification of synthetic lethal targets at the single-cell scale 3、TarFormer——Target identification driven by transcriptome perturbation data
